Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents mixed signals: strong gross profit margins and a significant increase in operating profit and net income indicate positive financial health. However, a notable revenue decline, uncertainties regarding IEEPA tariff refunds, and increased debt raise concerns. The Q&A section reveals management's vague responses about future investments, adding to the uncertainty. Shareholder returns through dividends and repurchases are modest, with no significant new partnerships or guidance changes. These factors suggest a neutral stock price movement over the next two weeks.
Revenue $122 million in Q1 2026, down 8.6% year-over-year from $103.4 million in Q1 2025. The decline was primarily driven by lower volumes in the U.S. consumer business, partially offset by higher prices and robust sales growth in the healthcare division.
Gross Profit $36.2 million in Q1 2026, up 10.4% year-over-year from $32.8 million in Q1 2025. The increase was due to favorable pricing and customer mix, partially offset by higher product costs.
Gross Profit Margin 29.7% in Q1 2026, up from 24.6% in Q1 2025, a 510-basis point improvement. This was driven by favorable pricing, customer mix, and a one-time benefit of 190 basis points from the sell-through of inventory priced in anticipation of IEEPA tariffs, which were eliminated. The remaining 320 basis points were due to timing of price increases and increased penetration of higher-margin commercial and healthcare businesses.
Operating Profit $5 million in Q1 2026, up 115% year-over-year from $2.3 million in Q1 2025. The increase was driven by strong gross margin gains.
Net Income $3.5 million in Q1 2026, up from $1.8 million in Q1 2025. This increase was attributed to higher operating profit.
Net Cash Provided by Operating Activities $3.3 million in Q1 2026, down from $6.6 million in Q1 2025. The decrease was primarily due to higher net working capital, including a planned increase in accounts receivable after exiting an arrangement to sell certain U.S. trade receivables, partially offset by lower incentive payouts.
Net Debt $2.6 million at the end of Q1 2026, up from $1.7 million at the end of Q1 2025. The increase was due to cash flow allocations for share repurchases and dividend payments.
Blender Kitchen Systems: Three new innovative blender kitchen systems are gaining traction in the market, bringing fresh innovation to one of the company's strongest categories.
Durathon Iron Platform: The redesigned Durathon iron platform launched during the quarter with exceptional reception, building success on an established Durathon technology.
Garment Steamers: Expansion into garment steamers with new models, positioning the company to capture share in this large and growing segment.
Single-Serve Coffee Platforms: Two new single-serve coffee platforms are set to launch in the second half of the year, bringing innovation to another important category.
Retail Expansion: Expanded several programs with a leading department store, added shelf space at two top wholesale membership clubs, and increased penetration with a leading mass market retailer.
Premium Market Growth: Lotus brand expansion continues to exceed expectations, with the fall launch of Lotus Signature and increased shelf space commitments from key retail partners.
Global Commercial Market: Deepening relationships with large food service and hospitality chains, with products like the Summit Edge blender and Eclipse blender gaining traction.
Gross Margin Expansion: Achieved a 510-basis point improvement in gross margin due to favorable pricing, customer mix, and tariff mitigation actions.
Digital Transformation: Increased investment in digital, social media, and influencer marketing, along with leveraging AI shopping tactics to improve discoverability and conversion.
Healthcare Division Growth: Healthcare division achieved its third consecutive quarter of profitable growth, with sales expected to increase by 50% this year.
Connected Medical Device Platform: Launching a pilot for a pill management platform in Q3, targeting oncology and mental health treatments, with plans to expand to other therapeutic areas.
Advertising Strategy: Selected a new advertising agency to oversee and drive digital marketing strategy starting in the second half of the year.
Consumer Spending Weakness: Discretionary spending weakened in parts of the business, particularly in the U.S. consumer segment, due to elevated fuel costs and economic pressures on shoppers.
Revenue Decline: First quarter revenue declined by 8.6% year-over-year, driven by lower volumes in the U.S. consumer business, partially offset by higher prices.
Nonrecurring Margin Benefit: A one-time benefit of 190 basis points in gross margin from the sell-through of inventory priced in anticipation of IEEPA tariffs will not persist beyond the affected inventory.
ERP System Depreciation: $1.4 million in accelerated depreciation of the legacy ERP system increased SG&A expenses, impacting profitability.
Cash Flow Timing Issues: Net cash provided by operating activities decreased due to higher net working capital, including a planned increase in accounts receivable after exiting a trade receivables arrangement.
IEEPA Tariff Refund Uncertainty: The company is pursuing $41 million in IEEPA-related tariff refunds, but the timing and ultimate recovery remain uncertain.
Driving growth of core business: Plans to launch two new single-serve coffee platforms in the second half of the year. Expansion into garment steamers and new product placements with leading retailers. Increased investment in digital, social media, and influencer marketing.
Accelerating digital transformation: Focus on improving discoverability across platforms and leveraging AI shopping tactics. Selection of a new advertising agency to drive digital marketing strategy starting in the second half of the year.
Gaining a larger share in the premium market: Expansion of the Lotus brand with the fall launch of Lotus Signature. Increased shelf space commitments from key retail partners.
Leading in the global commercial market: Expansion of commercial blender placements with large food service and hospitality chains. New placements for commercial juicers and sectionizers in restaurants, hospitality chains, and schools.
Accelerating growth of Hamilton Beach Health: Plans to increase sales by 50% in 2026. Launch of a new injectable drug on the Smart Sharps Bin platform and a pilot for a pill management platform in Q3 targeting oncology and mental health treatments.
Revenue Growth: Expected to approach the mid-single-digit range for 2026.
Gross Margins: Projected to be similar to or slightly better than 2025 levels, with reinvestment of Q1 margin upside into promotional programs.
Operating Profit: Expected to decline in the low teens percentage-wise due to increased advertising spend and accelerated depreciation of the legacy ERP system.
Cash Flow: Cash flow from operating activities less cash used for investing activities is expected to be in the $35 million to $45 million range for 2026.
IEEPA-related refunds: Potential recovery of approximately $41 million in tariffs paid in 2025 and early 2026, though timing and recovery remain uncertain.
Dividends Paid: During the first quarter of 2026, the company paid $1.6 million in dividends.
Share Repurchase: The company repurchased approximately 55,000 shares totaling $900,000 during the first quarter of 2026.
The earnings call presents mixed signals: strong gross profit margins and a significant increase in operating profit and net income indicate positive financial health. However, a notable revenue decline, uncertainties regarding IEEPA tariff refunds, and increased debt raise concerns. The Q&A section reveals management's vague responses about future investments, adding to the uncertainty. Shareholder returns through dividends and repurchases are modest, with no significant new partnerships or guidance changes. These factors suggest a neutral stock price movement over the next two weeks.
The earnings call shows mixed results: strong commercial and health division growth, positive operating profit, and increased gross margins are countered by declines in U.S. consumer business and full-year revenue. The Q&A highlights uncertainty in tariff impacts and lack of clarity on sales resumption details. While new partnerships and product pipelines offer future growth potential, increased costs and economic uncertainties pose risks. The combination of these factors suggests a neutral stock price movement over the next two weeks.
The earnings call highlights several concerns: a significant revenue decline, increased net debt, and cash flow issues due to shorter payment terms. Although there are positive developments like resumed orders from a large retailer and cost management measures, the lack of guidance and ongoing economic uncertainty overshadow these positives. The Q&A session did not alleviate concerns, especially regarding tariffs and financial pressures. These factors suggest a negative market reaction, likely leading to a stock price decline between -2% and -8% over the next two weeks.
The earnings call reveals several concerns: a significant revenue decline, increased net debt, and cash flow issues. Although there are positive aspects like improved gross margins and strategic initiatives, the suspension of guidance due to tariff unpredictability and the lack of clear growth projections weigh heavily. Share repurchases and cost-saving measures are positive, but the overall financial performance and uncertainties suggest a negative sentiment. The Q&A section confirms these concerns, with management avoiding direct answers on growth alignment with GDP, further justifying a negative outlook.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.